| Jayasree Seshadri, OD | |
|
91 Point Judith Rd, Suite #2, Narragansett, RI 02882-3445 | |
| (401) 782-2100 | |
| (401) 782-2101 |
| Full Name | Jayasree Seshadri |
|---|---|
| Gender | Female |
| Speciality | Optometry |
| Experience | 15 Years |
| Location | 91 Point Judith Rd, Narragansett, Rhode Island |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215167879 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | ODTG00541 (Rhode Island) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Edward M Kennedy Community Health Center Inc | 3476512740 | 62 |
News Archive
New Zealand based research on youth tobacco use suggests that current efforts to prevent school children smoking are not targeted early enough, as it found a significant number are already experimenting with tobacco by age seven.
The Government of the Grand Duchy of Luxembourg announced on June 5, 2008 the implementation of a strategic partnership initiative with three U.S. research institutions. As part of the initiative, the Government will invest approximately 140 million euros over the next five years as it aims to develop a centre of expertise in the area of molecular medicine.
A panel of biomarkers appears to be able to identify the presence of lung cancer in the blood samples of people who have never smoked, according to data presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.
TRIA Beauty, the leader in light-based therapeutic beauty devices, today announced it received over-the-counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a hand-held blue light device designed for at-home use.
BioAlliance Pharma SA today announced the preliminary positive results for its US pivotal Phase III clinical trial with Loramyc (miconazole Lauriad), Mucoadhesive Buccal Tablets (MBT) developed for the treatment of OroPharyngeal Candidiasis in immunocompromised population. This trial was conducted to support an NDA filing to market the product in the US.
› Verified 7 days ago
| Provider Name | Edward M Kennedy Community Health Center Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1609842152 PECOS PAC ID: 3476512740 Enrollment ID: O20041004000840 |
News Archive
New Zealand based research on youth tobacco use suggests that current efforts to prevent school children smoking are not targeted early enough, as it found a significant number are already experimenting with tobacco by age seven.
The Government of the Grand Duchy of Luxembourg announced on June 5, 2008 the implementation of a strategic partnership initiative with three U.S. research institutions. As part of the initiative, the Government will invest approximately 140 million euros over the next five years as it aims to develop a centre of expertise in the area of molecular medicine.
A panel of biomarkers appears to be able to identify the presence of lung cancer in the blood samples of people who have never smoked, according to data presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.
TRIA Beauty, the leader in light-based therapeutic beauty devices, today announced it received over-the-counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a hand-held blue light device designed for at-home use.
BioAlliance Pharma SA today announced the preliminary positive results for its US pivotal Phase III clinical trial with Loramyc (miconazole Lauriad), Mucoadhesive Buccal Tablets (MBT) developed for the treatment of OroPharyngeal Candidiasis in immunocompromised population. This trial was conducted to support an NDA filing to market the product in the US.
› Verified 7 days ago
| Provider Name | Mass Optometric Associates, Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1063610194 PECOS PAC ID: 0648362442 Enrollment ID: O20070824000362 |
News Archive
New Zealand based research on youth tobacco use suggests that current efforts to prevent school children smoking are not targeted early enough, as it found a significant number are already experimenting with tobacco by age seven.
The Government of the Grand Duchy of Luxembourg announced on June 5, 2008 the implementation of a strategic partnership initiative with three U.S. research institutions. As part of the initiative, the Government will invest approximately 140 million euros over the next five years as it aims to develop a centre of expertise in the area of molecular medicine.
A panel of biomarkers appears to be able to identify the presence of lung cancer in the blood samples of people who have never smoked, according to data presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.
TRIA Beauty, the leader in light-based therapeutic beauty devices, today announced it received over-the-counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a hand-held blue light device designed for at-home use.
BioAlliance Pharma SA today announced the preliminary positive results for its US pivotal Phase III clinical trial with Loramyc (miconazole Lauriad), Mucoadhesive Buccal Tablets (MBT) developed for the treatment of OroPharyngeal Candidiasis in immunocompromised population. This trial was conducted to support an NDA filing to market the product in the US.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jayasree Seshadri, OD 513 Francis Ave, Mansfield, MA 02048-1547 Ph: (781) 266-6904 | Jayasree Seshadri, OD 91 Point Judith Rd, Suite #2, Narragansett, RI 02882-3445 Ph: (401) 782-2100 |
News Archive
New Zealand based research on youth tobacco use suggests that current efforts to prevent school children smoking are not targeted early enough, as it found a significant number are already experimenting with tobacco by age seven.
The Government of the Grand Duchy of Luxembourg announced on June 5, 2008 the implementation of a strategic partnership initiative with three U.S. research institutions. As part of the initiative, the Government will invest approximately 140 million euros over the next five years as it aims to develop a centre of expertise in the area of molecular medicine.
A panel of biomarkers appears to be able to identify the presence of lung cancer in the blood samples of people who have never smoked, according to data presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.
TRIA Beauty, the leader in light-based therapeutic beauty devices, today announced it received over-the-counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a hand-held blue light device designed for at-home use.
BioAlliance Pharma SA today announced the preliminary positive results for its US pivotal Phase III clinical trial with Loramyc (miconazole Lauriad), Mucoadhesive Buccal Tablets (MBT) developed for the treatment of OroPharyngeal Candidiasis in immunocompromised population. This trial was conducted to support an NDA filing to market the product in the US.
› Verified 7 days ago
Optometric Providers Of Rhode Island, Inc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 91 Point Judith Rd, Narragansett, RI 02882 Phone: 401-782-2100 Fax: 401-782-2101 | |
Rhode Island Optometrics, Llc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 91 Point Judith Rd Ste 2, Narragansett, RI 02882 Phone: 401-782-2100 Fax: 401-782-2101 |